J. Bergmann, Le bon usage du m??dicament : d??finition, r??f??rentiels, p??rim??tre et champ d???application, Th??rapie, vol.63, issue.4
DOI : 10.2515/therapie:2008042

. Thérapie, 1 jul, pp.267-73, 2008.

T. Roblek, K. Trobec, A. Mrhar, and M. Lainscak, Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease, Archives of Medical Science, vol.5, issue.5, pp.920-952, 2014.
DOI : 10.5114/aoms.2014.46212

T. Toivo, J. A. Mikkola, K. Laine, and M. Airaksinen, Identifying high risk medications causing potential drug???drug interactions in outpatients: A prescription database study based on an online surveillance system, Research in Social and Administrative Pharmacy, vol.12, issue.4, pp.559-68, 2016.
DOI : 10.1016/j.sapharm.2015.09.004

L. Mallet, A. Spinewine, and A. Huang, The challenge of managing drug interactions in elderly people, The Lancet, vol.370, issue.9582
DOI : 10.1016/S0140-6736(07)61092-7

R. Goldberg, J. Mabee, L. Chan, and S. Wong, Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population La polymédication : définitions, mesures et enjeux Revue de la littérature et tests de mesure, Marlène Monégat et Catherine Sermet, Questions d'Economie de la Santé n°204, IRDES, dec 2014. 9, Disponible sur, pp.11-1347336, 1996.

S. Huang, J. Strong, L. Zhang, K. Reynolds, S. Nallani et al., New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies Prediction of in vivo drug?drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant, J Clin Pharmacol. 1 jun Drug Saf. 1 nov Br J Clin Pharmacol. nov, vol.483260, issue.6115, pp.508-526, 2005.

T. Vial, Drug interaction working group of the French National Agency of Medicine and Health Products Safety: missions and decision-making process [Internet]. [cité 30 août 2017] Disponible sur: http://www.edimark.fr/ 15

R. Seymour, P. Routledge, G. Miremont-salamé, M. Pérault-pochat, P. Noize et al., Important drug-drug interactions in the elderly Haramburu F, the EMIR Study Group on behalf of the French network of pharmacovigilance centres. Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study Hospitalisations and emergency department visits due to drug-drug interactions: a literature review Hospitalizations because of adverse drug reactions in elderly patients admitted through the emergency department: a prospective survey Hospital admissions/visits associated with drugdrug interactions: a systematic review and meta-analysis, Disponible sur485?94. 19. Bénard-Laribière A, pp.475-82, 1998.

B. Guthrie, B. Makubate, V. Hernandez-santiago, and T. Dreischulte, The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995???2010, BMC Medicine, vol.5, issue.1, pp.74-98, 1995.
DOI : 10.1007/s00228-013-1621-6

P. Stoll and L. Kopittke, Potential drug-drug interactions in hospitalized patients undergoing systemic chemotherapy: a prospective cohort study Determinants of under-reporting of adverse drug reactions: a systematic review, Int J Clin Pharm. jun Drug Saf, vol.3732, issue.251, pp.475-8419, 2009.

J. Aronson, Toward standardized reporting of drug interactions: the READI checklist for anecdotal reports, Expert Review of Clinical Pharmacology, vol.320, issue.7251, pp.399-409, 2015.
DOI : 10.1136/bmj.320.7251.1737

L. Magro, U. Moretti, L. R. Roquefeuil, L. Weill, A. Ricordeau et al., Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions French national health insurance information system and the permanent beneficiaries sample. Rev DÉpidémiologie Santé Publique, Expert Opin Drug Saf. jan aug, vol.1158, issue.14, pp.286-90, 2010.

S. Cossin, Interactions médicamenteuses : données liées et applications Médecine humaine et pathologie, 2016.

S. I. Cossin, F. Montastruc, A. Sommet, E. Bondon-guitton, G. Durrieu et al., The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France Potentially harmful drug-drug interactions in the elderly: a review Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re?evaluation of an established drug Disponible sur Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin, extraire le PDF du thesaurus des interactions médicamenteuses de l'ANSM [Internet]. 2017 Disponible sur767?75. 32687?93. 35. Schlit A690?3. 37. Capucci A, Piangerelli L, Ricciotti J, Gabrielli D, Guerra F. Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol, pp.1698-704, 2004.

H. Yamazaki, T. Nanki, N. Miyasaka, M. Harigai, A. Studer et al., Methotrexate and Trimethoprim-Sulfamethoxazole for Pneumocystis pneumonia Prophylaxis L'échantillon généraliste de bénéficiaires : représentativité, portée et limites, J Rheumatol. Prat Organ Soins. 1 dec, vol.3840, issue.43, pp.213-236, 2011.

T. Payne, L. Hines, R. Chan, S. Hartman, J. Kapusnik-uner et al., Recommendations to improve the usability of drug-drug interaction clinical decision support alerts, Journal of the American Medical Informatics Association, vol.22, issue.6, pp.1243-50, 2015.
DOI : 10.1093/jamia/ocv011

. Dans-cet-exemple, nous observons une proportion de co-délivrance AB supérieure à ce qui est attendu, le DS est > 1 et si cette association est connue comme à risque d'interaction alors nous obtenons un signal de mésusage potentiel